Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese SubjectsAn Open-Label, Single-Center, First-in-Human Study

被引：15
|
作者：
Luning Sun
Li Ding
Yongqing Wang
Wenjia Zhou
Zhengyu Yan
Weilin Sun
Hongwen Zhang
Ning Ou
Xiaoping Chen
机构：
[1] China Pharmaceutical University,
[2] First Affiliated Hospital of Nanjing Medical University,undefined
[3] Beijing Shiqiao Biological and Pharmaceutical Co. Ltd,undefined
来源：
Drugs in R&D | 2012年 / 12卷 / 1期
关键词：
Rhinitis; Intranasal Administration; Ipratropium Bromide; Lateral Nasal Wall; Aclidinium;
D O I：
10.2165/11599330-000000000-00000
中图分类号：
学科分类号：
摘要：
Background: Bencycloquidium bromide (BCQB) is a novel, potent and selective muscarinic M1/M3 receptor antagonist under development for the treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of BCQB in animals have been established in preclinical studies. However, no clinical pharmacokinetic data are available for BCQB in humans.
引用
收藏
页码：17 / 28
页数：11
相关论文
共 31 条
  • [1] Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese Subjects An Open-Label, Single-Center, First-in-Human Study
    Sun, Luning
    Ding, Li
    Wang, Yongqing
    Zhou, Wenjia
    Yan, Zhengyu
    Sun, Weilin
    Zhang, Hongwen
    Ou, Ning
    Chen, Xiaoping
    DRUGS IN R&D, 2012, 12 (01) : 17 - 28
  • [2] Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese SubjectsAn Open-Label, Sequential, Two-Cohort, Single-Centre Study
    Haiyan Li
    Kathleen Butler
    Li Yang
    Zhenghua Yang
    Renli Teng
    Clinical Drug Investigation, 2012, 32 : 87 - 97
  • [3] Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study
    Liu, Yani
    Zhou, Jiali
    Li, Zhongfang
    Yang, Chunxiao
    Wu, Jianhong
    Zhang, Yu
    Shi, Shaojun
    Li, Yunqiao
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (04) : 443 - 451
  • [4] Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study
    Yani Liu
    Jiali Zhou
    Zhongfang Li
    Chunxiao Yang
    Jianhong Wu
    Yu Zhang
    Shaojun Shi
    Yunqiao Li
    European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40 : 443 - 451
  • [5] Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
    Duanduan Cong
    Jie Song
    Yue Liu
    Yan Tan
    Wei Xue
    Xiaohui Liu
    Wenyuan Qi
    Jun Lu
    Xiaojuan Yuan
    Yongchun Zhou
    Ai-Min Hui
    Kexin Li
    Neurology and Therapy, 2022, 11 : 283 - 301
  • [6] Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
    Cong, Duanduan
    Song, Jie
    Liu, Yue
    Tan, Yan
    Xue, Wei
    Liu, Xiaohui
    Qi, Wenyuan
    Lu, Jun
    Yuan, Xiaojuan
    Zhou, Yongchun
    Hui, Ai-Min
    Li, Kexin
    NEUROLOGY AND THERAPY, 2022, 11 (01) : 283 - 301
  • [7] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ENSIFENTRINE IN HEALTHY CHINESE ADULTS: A PHASE 1, OPEN-LABEL, SINGLE AND MULTIPLE DOSE STUDY
    Meng, Haijin
    Li, Xin
    Chen, Charlie
    Cheng, Cecilia
    Zhang, Ping
    Yuan, Chenchen Zhang
    CHEST, 2024, 166 (04) : 4758A - 4758A
  • [8] Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
    Yani Liu
    Jianhong Wu
    Zhongfang Li
    Ying Luo
    Fandian Zeng
    Shaojun Shi
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 37 - 48
  • [9] Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
    Liu, Yani
    Wu, Jianhong
    Li, Zhongfang
    Luo, Ying
    Zeng, Fandian
    Shi, Shaojun
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (01) : 37 - 48
  • [10] First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects
    Zhang, Hong
    Gao, Lei
    Lou, Jinfeng
    Wu, Min
    Chen, Hong
    Yang, Lizhi
    Liu, Jingrui
    Zhu, Xiaoxue
    Li, Xiaojiao
    Li, Cuiyun
    Wang, Meng
    Liu, Chengjiao
    Guo, Weibo
    Wang, Yuan
    Gao, Zhongqiang
    Han, Lei
    Wang, Daidi
    Jin, Weili
    Ding, Yanhua
    FRONTIERS IN PHARMACOLOGY, 2022, 13
1234